(Circulation. 2001;103:2441.)
© 2001 American Heart Association, Inc.
Clinical Investigation and Reports |
Myocardial Free Fatty Acid and Glucose Use After Carvedilol Treatment in Patients With Congestive Heart Failure
From the William S. Middleton Veterans Hospital, Madison, Wis (T.R.W., D.C.R.); the Department of Medical Physics, University of Wisconsin—Madison, Madison, Wis (M.T., R.J.N.); the Department of Medical Physics, Duke University, Durham, NC (T.R.D.); and the Department of Medicine, University of Wisconsin—Madison, Madison Wis (T.R.W., D.C.R., P.S., C.K.S.).
Correspondence and reprint requests to Thomas R. Wallhaus, MD, 600 Highland Ave, H6/349, University of Wisconsin Hospital and Clinics, Department of Medicine, Cardiology Section, Madison, WI 53792-3248. E-mail trw{at}medicine.wisc.edu
Background—Use of ß-adrenoreceptor blockade in the treatment of heart failure has been associated with a reduction in myocardial oxygen consumption and an improvement in myocardial energy efficiency. One potential mechanism for this beneficial effect is a shift in myocardial substrate use from increased free fatty acid (FFA) oxidation to increased glucose oxidation.
Methods and Results—We
studied the effect of carvedilol therapy on myocardial FFA and glucose
use in 9 patients with stable New York Heart Association functional
class III ischemic cardiomyopathy (left
ventricular ejection fraction 
35%) using myocardial
positron emission tomography studies and resting echocardiograms before
and 3 months after carvedilol treatment. Myocardial uptake of the novel
long chain fatty acid metabolic tracer 14(R,
S)-[18F]fluoro-6-thia-heptadecanoic acid
([18F]-FTHA) was used to determine
myocardial FFA use, and
[18F]fluoro-2-deoxy-glucose
([18F]-FDG) was used to determine
myocardial glucose use. After carvedilol treatment, the mean
myocardial uptake rate for [18F]-FTHA
decreased (from 20.4±8.6 to 9.7±2.3 mL · 100
g–1 · min–1;
P<0.005), mean fatty acid use
decreased (from 19.3±7.0 to 8.2±1.8 µmoL · 100
g–1 · min–1;
P<0.005), the mean myocardial
uptake rate for [18F]-FDG was unchanged
(from 1.4±0.4 to 2.4±0.8 mL · 100 g–1
· min–1;
P=0.14), and mean glucose use
was unchanged (from 11.1±3.1 to 18.7±6.0 µmoL · 100
g–1 · min–1;
P=0.12). Serum FFA and glucose
concentrations were unchanged, and mean left ventricular
ejection fraction improved (from 26±2% to 37±4%;
P<0.05).
Conclusions—Carvedilol treatment in patients with heart failure results in a 57% decrease in myocardial FFA use without a significant change in glucose use. These metabolic changes could contribute to the observed improvements in energy efficiency seen in patients with heart failure.
Key Words: fatty acids • glucose • metabolism • heart failure
This article has been cited by other articles:
 |
|
 |
|
  H. Tuunanen, E. Engblom, A. Naum, K. Nagren, M. Scheinin, B. Hesse, K.E. Juhani Airaksinen, P. Nuutila, P. Iozzo, H. Ukkonen, et al. Trimetazidine, a Metabolic Modulator, Has Cardiac and Extracardiac Benefits in Idiopathic Dilated Cardiomyopathy Circulation, September 16, 2008; 118(12): 1250 - 1258. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. H. Opie Metabolic Management of Acute Myocardial Infarction Comes to the Fore and Extends Beyond Control of Hyperglycemia Circulation, April 29, 2008; 117(17): 2172 - 2177. [Full Text] [PDF]
|
|
|
|
 |
|
 R. M. Witteles and M. B. Fowler Insulin-Resistant Cardiomyopathy: Clinical Evidence, Mechanisms, and Treatment Options J. Am. Coll. Cardiol., January 15, 2008; 51(2): 93 - 102. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 D. Neglia, A. De Caterina, P. Marraccini, A. Natali, M. Ciardetti, C. Vecoli, A. Gastaldelli, D. Ciociaro, P. Pellegrini, R. Testa, et al. Impaired myocardial metabolic reserve and substrate selection flexibility during stress in patients with idiopathic dilated cardiomyopathy Am J Physiol Heart Circ Physiol, December 1, 2007; 293(6): H3270 - H3278. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Muniyappa, M. Montagnani, K. K. Koh, and M. J. Quon Cardiovascular Actions of Insulin Endocr. Rev., August 1, 2007; 28(5): 463 - 491. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Ashrafian, M. P. Frenneaux, and L. H. Opie Metabolic Mechanisms in Heart Failure Circulation, July 24, 2007; 116(4): 434 - 448. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Neubauer The Failing Heart -- An Engine Out of Fuel N. Engl. J. Med., March 15, 2007; 356(11): 1140 - 1151. [Full Text] [PDF]
|
|
|
|
|
|
H. Tuunanen, E. Engblom, A. Naum, K. Nagren, B. Hesse, K. E. J. Airaksinen, P. Nuutila, P. Iozzo, H. Ukkonen, L. H. Opie, et al. Free Fatty Acid Depletion Acutely Decreases Cardiac Work and Efficiency in Cardiomyopathic Heart Failure Circulation, November 14, 2006; 114(20): 2130 - 2137. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. D. Lopaschuk Optimizing cardiac Fatty Acid and glucose metabolism as an approach to treating heart failure. Seminars in Cardiothoracic and Vascular Anesthesia, September 1, 2006; 10(3): 228 - 230. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Groban and J. Butterworth Perioperative management of chronic heart failure. Anesth. Analg., September 1, 2006; 103(3): 557 - 575. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. Pilz, H. Scharnagl, B. Tiran, U. Seelhorst, B. Wellnitz, B. O. Boehm, J. R. Schaefer, and W. Marz Free Fatty Acids Are Independently Associated with All-Cause and Cardiovascular Mortality in Subjects with Coronary Artery Disease J. Clin. Endocrinol. Metab., July 1, 2006; 91(7): 2542 - 2547. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Nikolaidis, I. Poornima, P. Parikh, M. Magovern, Y.-T. Shen, and R. P. Shannon The Effects of Combined Versus Selective Adrenergic Blockade on Left Ventricular and Systemic Hemodynamics, Myocardial Substrate Preference, and Regional Perfusion in Conscious Dogs With Dilated Cardiomyopathy J. Am. Coll. Cardiol., May 2, 2006; 47(9): 1871 - 1881. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 G. Fragasso, G. Perseghin, F. De Cobelli, A. Esposito, A. Palloshi, G. Lattuada, P. Scifo, G. Calori, A. Del Maschio, and A. Margonato Effects of metabolic modulation by trimetazidine on left ventricular function and phosphocreatine/adenosine triphosphate ratio in patients with heart failure Eur. Heart J., April 2, 2006; 27(8): 942 - 948. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 Y. Liao, S. Takashima, H. Zhao, Y. Asano, Y. Shintani, T. Minamino, J. Kim, M. Fujita, M. Hori, and M. Kitakaze Control of plasma glucose with alpha-glucosidase inhibitor attenuates oxidative stress and slows the progression of heart failure in mice Cardiovasc Res, April 1, 2006; 70(1): 107 - 116. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 S. S. Hamdulay, A. A. Khafaji, and H. Montgomery Glucose-Insulin and Potassium Infusions in Septic Shock Chest, March 1, 2006; 129(3): 800 - 804. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Ghio, G. Magrini, A. Serio, C. Klersy, A. Fucilli, A. Ronaszeki, P. Karpati, G. Mordenti, A. Capriati, P. A. Poole-Wilson, et al. Effects of nebivolol in elderly heart failure patients with or without systolic left ventricular dysfunction: results of the SENIORS echocardiographic substudy Eur. Heart J., March 1, 2006; 27(5): 562 - 568. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
W. Doehner, M. Rauchhaus, P. Ponikowski, I. F. Godsland, S. von Haehling, D. O. Okonko, F. Leyva, A. J. Proudler, A. J.S. Coats, and S. D. Anker Impaired Insulin Sensitivity as an Independent Risk Factor for Mortality in Patients With Stable Chronic Heart Failure J. Am. Coll. Cardiol., September 20, 2005; 46(6): 1019 - 1026. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
H. Wiggers, H. Norrelund, S. S. Nielsen, N. H. Andersen, J. E. Nielsen-Kudsk, J. S. Christiansen, T. T. Nielsen, N. Moller, and H. E. Botker Influence of insulin and free fatty acids on contractile function in patients with chronically stunned and hibernating myocardium Am J Physiol Heart Circ Physiol, August 1, 2005; 289(2): H938 - H946. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 W. C. Stanley, F. A. Recchia, and G. D. Lopaschuk Myocardial Substrate Metabolism in the Normal and Failing Heart Physiol Rev, July 1, 2005; 85(3): 1093 - 1129. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
C. S. Apstein and L. H. Opie A challenge to the metabolic approach to myocardial ischaemia Eur. Heart J., May 2, 2005; 26(10): 956 - 959. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 E O'Meara and J J V McMurray Myocardial metabolic manipulation: a new therapeutic approach in heart failure? Heart, February 1, 2005; 91(2): 131 - 132. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Nemoto, P. Razeghi, M. Ishiyama, G. De Freitas, H. Taegtmeyer, and B. A. Carabello PPAR-{gamma} agonist rosiglitazone ameliorates ventricular dysfunction in experimental chronic mitral regurgitation Am J Physiol Heart Circ Physiol, January 1, 2005; 288(1): H77 - H82. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. Scheuer Fueling the Hypertrophied Heart Hypertension, November 1, 2004; 44(5): 623 - 624. [Full Text] [PDF]
|
|
|
|
|
|
M. P. Chandler, J. Kerner, H. Huang, E. Vazquez, A. Reszko, W. Z. Martini, C. L. Hoppel, M. Imai, S. Rastogi, H. N. Sabbah, et al. Moderate severity heart failure does not involve a downregulation of myocardial fatty acid oxidation Am J Physiol Heart Circ Physiol, October 1, 2004; 287(4): H1538 - H1543. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. A. Nikolaidis, D. Elahi, T. Hentosz, A. Doverspike, R. Huerbin, L. Zourelias, C. Stolarski, Y.-t. Shen, and R. P. Shannon Recombinant Glucagon-Like Peptide-1 Increases Myocardial Glucose Uptake and Improves Left Ventricular Performance in Conscious Dogs With Pacing-Induced Dilated Cardiomyopathy Circulation, August 24, 2004; 110(8): 955 - 961. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
L. Lee, J. Horowitz, and M. Frenneaux Metabolic manipulation in ischaemic heart disease, a novel approach to treatment Eur. Heart J., April 2, 2004; 25(8): 634 - 641. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
S. Hasegawa, H. Kusuoka, K. Maruyama, T. Nishimura, M. Hori, and J. Hatazawa Myocardial positron emission computed tomographic images obtained with fluorine-18 fluoro-2-deoxyglucose predict the response of idiopathic dilated cardiomyopathy patients to beta-blockers J. Am. Coll. Cardiol., January 21, 2004; 43(2): 224 - 233. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Czubryt and E. N. Olson Balancing Contractility and Energy Production: The Role of Myocyte Enhancer Factor 2 (MEF2) in Cardiac Hypertrophy Recent Prog. Horm. Res., January 1, 2004; 59(1): 105 - 124. [Abstract] [Full Text]
|
|
|
|
|
|
F. D. Russell, D. Meyers, A. J. Galbraith, N. Bett, I. Toth, P. Kearns, and P. Molenaar Elevated plasma levels of human urotensin-II immunoreactivity in congestive heart failure Am J Physiol Heart Circ Physiol, October 1, 2003; 285(4): H1576 - H1581. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
K. Q. Stolen, J. Kemppainen, H. Ukkonen, K. K. Kalliokoski, M. Luotolahti, P. Lehikoinen, H. Hamalainen, T. Salo, K. E. Juhani Airaksinen, P. Nuutila, et al. Exercise training improves biventricular oxidative metabolism and left ventricular efficiency in patients with dilated cardiomyopathy J. Am. Coll. Cardiol., February 5, 2003; 41(3): 460 - 467. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V K Khoury, B Haluska, J Prins, and T H Marwick Effects of glucose-insulin-potassium infusion on chronic ischaemic left ventricular dysfunction Heart, January 1, 2003; 89(1): 61 - 65. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. Bartnik, K. Malmberg, and L. Ryden Diabetes and the heart: compromised myocardial function -- a common challenge Eur. Heart J. Suppl., January 1, 2003; 5(suppl_B): B33 - B41. [Abstract] [PDF]
|
|
|
|
 |
|
 P. Herrero, T. L. Sharp, C. Dence, B. M. Haraden, and R. J. Gropler Comparison of 1-11C-Glucose and 18F-FDG for Quantifying Myocardial Glucose Use with PET J. Nucl. Med., November 1, 2002; 43(11): 1530 - 1541. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
R. Liao, M. Jain, L. Cui, J. D'Agostino, F. Aiello, I. Luptak, S. Ngoy, R. M. Mortensen, and R. Tian Cardiac-Specific Overexpression of GLUT1 Prevents the Development of Heart Failure Attributable to Pressure Overload in Mice Circulation, October 15, 2002; 106(16): 2125 - 2131. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 M. P. Chandler, W. C. Stanley, H. Morita, G. Suzuki, B. A. Roth, B. Blackburn, A. Wolff, and H. N. Sabbah Short-Term Treatment With Ranolazine Improves Mechanical Efficiency in Dogs With Chronic Heart Failure Circ. Res., August 23, 2002; 91(4): 278 - 280. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
V.i. G. Davila-Roman, G. Vedala, P. Herrero, L. de las Fuentes, J. G. Rogers, D. P. Kelly, and R. J. Gropler Altered myocardial fatty acid and glucose metabolism in idiopathic dilated cardiomyopathy J. Am. Coll. Cardiol., July 17, 2002; 40(2): 271 - 277. [Abstract] [Full Text] [PDF]
|
|
|
|
|
|
J. Marin-Garcia and M. J. Goldenthal Fatty acid metabolism in cardiac failure: biochemical, genetic and cellular analysis Cardiovasc Res, June 1, 2002; 54(3): 516 - 527. [Full Text] [PDF]
|
|
|
|
|
|
H. Ashrafian, E. Johannsson, O. M. Sejersted, P. K. Lunde, I. Sjaastad, M. J. Thomas, L. Bergersen, T. W. Blackstad, O. P. Ottersen, C. Heddle, et al. Cardiac Energetics in Congestive Heart Failure Response Circulation, February 12, 2002; 105 (6): e44 - e45. [Full Text] [PDF]
|
|
|
|
|
|
P. Razeghi, M. E. Young, J. L. Alcorn, C. S. Moravec, O.H. Frazier, and H. Taegtmeyer Metabolic Gene Expression in Fetal and Failing Human Heart Circulation, December 11, 2001; 104(24): 2923 - 2931. [Abstract] [Full Text] [PDF]
|
|